Literature DB >> 29068494

Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.

H Zetterberg1,2,3,4.   

Abstract

Although it is clear that the immune system is an important disease driver in multiple sclerosis (MS), it is presently unknown what initiates the process. Infections have been mentioned as potential triggers, which is specifically dealt with in other articles of this volume. Here, I give an overview of two fluid biomarkers that reflect key elements of the MS process: microglial activation (cerebrospinal fluid [CSF] sTREM2) and axonal injury (CSF and serum/plasma neurofilament light). I review recent data on how these markers are altered in MS, how they change in relation to disease progression and treatment and, finally, how they can be used as tools in MS research.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  axonal injury; biomarkers; cerebrospinal fluid; microglia; multiple sclerosis; plasma; serum

Mesh:

Substances:

Year:  2017        PMID: 29068494     DOI: 10.1111/ane.12845

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Authors:  Jeppe Romme Christensen; Mika Komori; Marina Rode von Essen; Rikke Ratzer; Lars Börnsen; Bibi Bielekova; Finn Sellebjerg
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

Review 2.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

3.  Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study.

Authors:  M N Olesen; K Soelberg; B Debrabant; A C Nilsson; S T Lillevang; J Grauslund; I Brandslund; J S Madsen; F Paul; T J Smith; S Jarius; N Asgari
Journal:  J Neuroinflammation       Date:  2019-03-11       Impact factor: 8.322

4.  CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study.

Authors:  Ming-Hao Dong; Luo-Qi Zhou; Yue Tang; Man Chen; Jun Xiao; Ke Shang; Gang Deng; Chuan Qin; Dai-Shi Tian
Journal:  J Neuroinflammation       Date:  2022-04-05       Impact factor: 8.322

5.  Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis.

Authors:  Zara A Ioannides; Peter A Csurhes; Andrew Swayne; Philippe Foubert; Blake T Aftab; Michael P Pender
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-06-03

Review 6.  Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics.

Authors:  Catarina M Abreu; Ricardo Soares-Dos-Reis; Pedro N Melo; João B Relvas; Joana Guimarães; Maria José Sá; Andrea P Cruz; Inês Mendes Pinto
Journal:  Front Mol Neurosci       Date:  2018-05-16       Impact factor: 5.639

Review 7.  Microglial Pruning: Relevance for Synaptic Dysfunction in Multiple Sclerosis and Related Experimental Models.

Authors:  Maria Concetta Geloso; Nadia D'Ambrosi
Journal:  Cells       Date:  2021-03-20       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.